<DOC>
	<DOCNO>NCT01409564</DOCNO>
	<brief_summary>The purpose study examine effect cilostazol augmentation mild moderate Alzheimer disease patient subcortical white matter hyperintensities ( WMHI ) treat donepezil . Dementia disable disease old age . The prevalence dementia 5-10 % elder . AchEIs ( donepezil , galantamine , rivastigmine ) use treat mild moderate dementia , drug relate symptomatic improvement response rate less 30 % . Cilostazol cyclic adenosine monophosphate phosphodiesterase 3 inhibitor ( PDE3I ) use antiplatelet agent subcortical vascular disease ( WMHI ) . And upregulates phosphorylation cyclic adenosine monophosphate-pathway response element bind protein ( CREB ) play crucial role memory enhancement synaptic plasticity relate neurodegeneration prevention . The investigator try cilostazol augmentation dementia patient WMHI receive donepezil see addictive effect cilostazol use cognitive task PET imaging .</brief_summary>
	<brief_title>Cilostazol Augmentation Study Dementia</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Men/women sixty year old Patients slight moderate dementia ( MMSE score 10 26 . ) Patients probable Alzheimer 's disease accord standard NINCDSADRDA Patients accompany WMHI Brain MRI ( Fazeka 's scale 1~3 ) Those agree test write form Patients accompany disease except cerebral atrophy change subcortical white matter due Alzheimer 's disease brain MRI Patients use Cilostazol ( ① patient bleed tendency ② patient congestive heart failure ③ patient medical history hypersensitivity medicine constituent medicine ④ use anticoagulant clot buster ) Patients suffer nerve disease mental disease influence cognitive function except Alzheimer 's disease ( example , schizophrenia , severe depression , mental retardation etc . ) Patients suspected personal history drug addiction alcoholism within recent 10 year Patients severe problem eye sight hear impossible conduct test smoothly Patients researcher think inappropriate take part test</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Alzheimer 's dementia</keyword>
	<keyword>Cilostazol</keyword>
</DOC>